Saturday, December 3, 2022


Biotechnology News Magazine

QleanAir Partnership to Support Work of Two Faculty Members Aiming to Reduce Occurrences of Contamination in Compounding Pharmacies with AI

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

UNC Eshelman School of Pharmacy’s Stephen Eckel, Pharm.D., M.H.A. and Robert Hubal, Ph.D, a research scientist at RENCI, are working to reduce occurrences of contamination in compounding pharmacies using artificial intelligence.

A partnership with QleanAir, along with previous grant support from the Eshelman Institute for Innovation (EII), will drive their work forward.

– As a global company with focus in healthcare, we are dedicated to protecting people, products, and processes. We are pleased to support the development of tomorrow’s technology to improve upon patient safety, drive operational compliance, and to enhance sterile compounding practices, said Amanda Myers, Chief Commercial Officer QleanAir Scandinavia Inc.

Eckel and Hubal are developing a technology that focuses on assessing an individual’s aseptic technique when preparing a compounded sterile product. Aseptic technique is the set of rules put in place to minimize the potential of contaminating a sterile product when pharmacists are compounding medications.

By using these funds, they have developed a solution that tracks both the compounding products and hand movements of individuals when they are compounding sterile products by utilizing multiple video cameras placed under a sterile compounding hood. Artificial intelligence will then compare those movements against established best practices.

Following the completion of each product preparation, individuals would receive performance reports, including any breaches of technique and steps to resolve for future preparations, Hubal said.

Ideally, the feedback would be used for a variety of reasons, including training new individuals, ongoing competency of personnel who prepare sterile products, or providing documentation to regulators to demonstrate ongoing quality assurance within the pharmacy.

– Our goal is to reduce the possibility of human error that can potentially occur when compounding medications, Eckel said. Ultimately, through this developed technology we have the ability to keep patients safe through appropriate aseptic technique, which is not doable within the current state of practice.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine